Lantheus Holdings (LNTH)

$81.31 -2.52 (-3.01%)
Market Cap 5.63B
Revenue (ttm) 1.53B
Net Income (ttm) 312.44M
EPS (ttm) N/A
PE Ratio 14.63
Forward PE 14.64
Profit Margin 20.37%
Debt to Equity Ratio 0.49
Volume 816,800
Avg Vol 1,210,078
Day's Range N/A - N/A
Shares Out 69.19M
Stochastic %K 42%
Beta 0.12
Analysts Strong Sell
Price Target $129.62

Company Profile

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area wi...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 978 671 8001
Fax: 978 671 8860
Address:
201 Burlington Road, South Building, Bedford, United States
RadioIsotope25
RadioIsotope25 Jul. 11 at 5:53 PM
$RADX Lutetium 177 is a blockbuster isotope fda approved for prostate cancer. Radiopharm Theranostics has 2 therapeutics using it targeting Breast and Lung cancer- they are backed by the Tesla of Radiopharmaceutical’s Lantheus having invested in January upping their position to 12% with most recent buy at the currency adjusted price of $11.75… https://www.facebook.com/share/v/1Huo4Ed5J1/?mibextid=wwXIfr $LNTH $CATX $NNE
0 · Reply
TPTradingCo
TPTradingCo Jul. 10 at 9:44 PM
$LNTH this 1-year price action funk is about to bid adieu, friend-o...
1 · Reply
RadioIsotope25
RadioIsotope25 Jul. 10 at 7:22 PM
$RADX Lantheus is moving back up nicely. $LNTH
0 · Reply
RadioIsotope25
RadioIsotope25 Jul. 8 at 1:27 PM
$LNTH Lantheus investing in this co https://m.youtube.com/watch?v=OjzgnRS7b98
0 · Reply
ChromeOnTheWheels
ChromeOnTheWheels Jul. 7 at 11:22 PM
$CPRX Impatient traders. Same story with $LNTH , another gem and long term gainer.
0 · Reply
ChromeOnTheWheels
ChromeOnTheWheels Jul. 3 at 8:50 PM
$LNTH and $CPRX are great longterm holds.
0 · Reply
RadioIsotope25
RadioIsotope25 Jul. 3 at 12:52 PM
$RADX Lantheus just bought more shares in Radiopharm Theranostics at $11.70… 7.50 upside to their buy price! Over their past 3 acquisitions they have paid $300 mil avg which implies 900% upside since market cap around $33 million. + major insider buying + tiny market cap + broad diversity in pipeline imaging and therapeutic isotopes + md anderson creating 4 new therapeutics for them + mid stage low risk brain imaging agent pivalate all signs it’s going well. + pdl-1 and her2 targeting therapeutics targeting huge billion dollar cancer markets lung cancer and breast. $INMB $LNTH
2 · Reply
RADX_enjoyer
RADX_enjoyer Jun. 24 at 1:06 PM
$RADX cashed up and kicking goals. No wonder $LNTH loves the look of Radiopharm Theranostics. Lantheus owns 12.12% of the company and continues to partner up with trials in Australia and the US!
1 · Reply
JarvisFlow
JarvisFlow Jun. 23 at 6:08 PM
B. Riley Securities updates rating for Lantheus Holdings ( $LNTH ) to Buy, target set at 122 → 109.
0 · Reply
RadioIsotope25
RadioIsotope25 Jun. 23 at 1:13 PM
$RADX The Best Buy recommendation comes from Lantheus they bought 12% of company last investment at 150% premium. Who does that? Last entry point $11.70 by $LNTH $CATX
1 · Reply
Latest News on LNTH
Lantheus Seems Worth The (Very Real) Risks

Jul 1, 2025, 7:28 AM EDT - 12 days ago

Lantheus Seems Worth The (Very Real) Risks

Lantheus Announces Presentations to be featured at the 2025 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting

Jun 11, 2025, 4:01 PM EDT - 4 weeks ago

Lantheus Announces Presentations to be featured at the 2025 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting

Lantheus to Present at the 2025 Truist Securities MedTech Conference

Jun 10, 2025, 8:30 AM EDT - 4 weeks ago

Lantheus to Present at the 2025 Truist Securities MedTech Conference

PharmaLogic Announces Appointment of Etienne Montagut as President and Chief Executive Officer

Jun 2, 2025, 8:00 AM EDT - 5 weeks ago

PharmaLogic Announces Appointment of Etienne Montagut as President and Chief Executive Officer

GEHC

Lantheus Holdings: Poor Results Caused By Temporary Problems - A Buy

May 14, 2025, 3:26 PM EDT - 2 months ago

Lantheus Holdings: Poor Results Caused By Temporary Problems - A Buy

Lantheus Holdings, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - LNTH

May 8, 2025, 6:50 PM EDT - 2 months ago

Lantheus Holdings, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - LNTH

Lantheus Holdings, Inc. (LNTH) Q1 2025 Earnings Call Transcript

May 7, 2025, 11:23 AM EDT - 2 months ago

Lantheus Holdings, Inc. (LNTH) Q1 2025 Earnings Call Transcript

Lantheus Announces Sale of SPECT Business to SHINE Technologies

May 6, 2025, 4:01 PM EDT - 2 months ago

Lantheus Announces Sale of SPECT Business to SHINE Technologies

Lantheus Announces Alzheimer's Disease Radiodiagnostic MK-6240 Meets Co-Primary Endpoints in Two Pivotal Studies

Apr 30, 2025, 8:30 AM EDT - 2 months ago

Lantheus Announces Alzheimer's Disease Radiodiagnostic MK-6240 Meets Co-Primary Endpoints in Two Pivotal Studies

Lantheus to Host First Quarter 2025 Earnings Conference Call and Webcast on May 7, 2025, at 8:00 a.m. Eastern Time

Apr 23, 2025, 8:30 AM EDT - 2 months ago

Lantheus to Host First Quarter 2025 Earnings Conference Call and Webcast on May 7, 2025, at 8:00 a.m. Eastern Time

Lantheus Completes Acquisition of Evergreen Theragnostics

Apr 1, 2025, 9:00 AM EDT - 3 months ago

Lantheus Completes Acquisition of Evergreen Theragnostics

Lantheus Holdings: Pylarify Makes Bull Case Despite Looming Patent Expiry

Mar 7, 2025, 11:12 AM EST - 4 months ago

Lantheus Holdings: Pylarify Makes Bull Case Despite Looming Patent Expiry

Lantheus Holdings, Inc. (LNTH) Q4 2024 Earnings Call Transcript

Feb 26, 2025, 10:49 AM EST - 4 months ago

Lantheus Holdings, Inc. (LNTH) Q4 2024 Earnings Call Transcript

Lantheus Appoints Phuong Khanh (P.K.) Morrow, M.D.

Jan 30, 2025, 8:30 AM EST - 5 months ago

Lantheus Appoints Phuong Khanh (P.K.) Morrow, M.D.

Lantheus to Acquire Evergreen Theragnostics for Upfront Payment of $250 Million to Drive Strategic Evolution into Fully Integrated Radiopharmaceutical Leader

Jan 28, 2025, 6:30 AM EST - 5 months ago

Lantheus to Acquire Evergreen Theragnostics for Upfront Payment of $250 Million to Drive Strategic Evolution into Fully Integrated Radiopharmaceutical Leader

Lantheus to Acquire Life Molecular Imaging for an Upfront Payment of $350 Million to Accelerate Innovation for Patients in the Growing Alzheimer's Disease Radiodiagnostic Market

Jan 13, 2025, 12:05 AM EST - 6 months ago

Lantheus to Acquire Life Molecular Imaging for an Upfront Payment of $350 Million to Accelerate Innovation for Patients in the Growing Alzheimer's Disease Radiodiagnostic Market

Lantheus Holdings: Powerhouse Potential In 2025

Jan 1, 2025, 7:43 PM EST - 6 months ago

Lantheus Holdings: Powerhouse Potential In 2025

Lantheus Holdings: A Growing Business With Dominant Market Share

Dec 12, 2024, 2:01 PM EST - 7 months ago

Lantheus Holdings: A Growing Business With Dominant Market Share

Lantheus Announces Share Repurchase Program

Nov 20, 2024, 1:00 AM EST - 8 months ago

Lantheus Announces Share Repurchase Program

Lantheus to Present at the Jefferies London Healthcare Conference

Nov 13, 2024, 8:30 AM EST - 8 months ago

Lantheus to Present at the Jefferies London Healthcare Conference

Lantheus Continues to Commend CMS' CY25 Rule to Enhance Payment for Specialized Diagnostic Radiopharmaceuticals and Reaffirms Outlook for PYLARIFY's Blockbuster Status for 2025

Nov 11, 2024, 7:39 AM EST - 8 months ago

Lantheus Continues to Commend CMS' CY25 Rule to Enhance Payment for Specialized Diagnostic Radiopharmaceuticals and Reaffirms Outlook for PYLARIFY's Blockbuster Status for 2025

Lantheus Holdings: Q3 Results Were Good But Market Overreacted

Nov 8, 2024, 10:06 AM EST - 8 months ago

Lantheus Holdings: Q3 Results Were Good But Market Overreacted

Lantheus Holdings, Inc. (LNTH) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 11:27 AM EST - 8 months ago

Lantheus Holdings, Inc. (LNTH) Q3 2024 Earnings Call Transcript

Lantheus Applauds CMS' CY25 Rule to Enhance Payment for Specialized Diagnostic Radiopharmaceuticals, Advancing Patient Access and Care

Nov 4, 2024, 7:30 AM EST - 8 months ago

Lantheus Applauds CMS' CY25 Rule to Enhance Payment for Specialized Diagnostic Radiopharmaceuticals, Advancing Patient Access and Care

Lantheus to Host Third Quarter 2024 Earnings Conference Call and Webcast on November 6, 2024, at 8:00 a.m. Eastern Time

Oct 23, 2024, 8:30 AM EDT - 9 months ago

Lantheus to Host Third Quarter 2024 Earnings Conference Call and Webcast on November 6, 2024, at 8:00 a.m. Eastern Time

Lantheus Presents Results from the Primary Analysis of Phase 3 Pivotal SPLASH Trial in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer During ESMO Congress 2024

Sep 15, 2024, 8:45 AM EDT - 10 months ago

Lantheus Presents Results from the Primary Analysis of Phase 3 Pivotal SPLASH Trial in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer During ESMO Congress 2024

Lantheus Appoints Julie Eastland as New Board Member

Sep 5, 2024, 8:30 AM EDT - 11 months ago

Lantheus Appoints Julie Eastland as New Board Member

Lantheus to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 28, 2024, 8:30 AM EDT - 11 months ago

Lantheus to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

Lantheus: A Radiopharmaceutical Powerhouse In The Making (Q2 2024 Update)

Aug 12, 2024, 3:32 PM EDT - 11 months ago

Lantheus: A Radiopharmaceutical Powerhouse In The Making (Q2 2024 Update)

13 stocks to consider if you're able to brave recession fears

Aug 12, 2024, 7:15 AM EDT - 11 months ago

13 stocks to consider if you're able to brave recession fears

CWAN ESNT FUL ISRG KO MA MKTX

Lantheus Holdings, Inc. (LNTH) Q2 2024 Earnings Call Transcript

Jul 31, 2024, 12:18 PM EDT - 1 year ago

Lantheus Holdings, Inc. (LNTH) Q2 2024 Earnings Call Transcript

Lantheus Reports Second Quarter 2024 Financial Results

Jul 31, 2024, 7:00 AM EDT - 1 year ago

Lantheus Reports Second Quarter 2024 Financial Results

10 Stocks That Star Small-Cap Funds Love

Jul 29, 2024, 2:00 AM EDT - 1 year ago

10 Stocks That Star Small-Cap Funds Love

ATKR AZEK FIX FN HQY MOD MTDR

Lantheus to Host Second Quarter 2024 Earnings Conference Call and Webcast on July 31, 2024, at 8:00 a.m. Eastern Time

Jul 17, 2024, 8:30 AM EDT - 1 year ago

Lantheus to Host Second Quarter 2024 Earnings Conference Call and Webcast on July 31, 2024, at 8:00 a.m. Eastern Time

Lantheus Acquires NAV-4694, a Next-Generation ß Amyloid PET Imaging Agent for Alzheimer's Disease

Jul 15, 2024, 8:30 AM EDT - 1 year ago

Lantheus Acquires NAV-4694, a Next-Generation ß Amyloid PET Imaging Agent for Alzheimer's Disease

Lantheus' Strategic Advantage Amplified By New CMS Payment Refinements (Rating Upgrade)

Jul 12, 2024, 11:40 AM EDT - 1 year ago

Lantheus' Strategic Advantage Amplified By New CMS Payment Refinements (Rating Upgrade)

Lantheus Welcomes CMS' Proposed CY25 Rule for Improved Payment for Specialized Diagnostic Radiopharmaceuticals to Support Patient Access

Jul 10, 2024, 12:32 PM EDT - 1 year ago

Lantheus Welcomes CMS' Proposed CY25 Rule for Improved Payment for Specialized Diagnostic Radiopharmaceuticals to Support Patient Access

Lantheus Appoints Jamie Spaeth as Chief People Officer

Jul 8, 2024, 8:30 AM EDT - 1 year ago

Lantheus Appoints Jamie Spaeth as Chief People Officer

Lantheus Acquires Global Rights to Life Molecular Imaging's Novel Therapeutic and Diagnostic Pair Targeting GRPR for Prostate and Breast Cancers

Jun 27, 2024, 7:05 AM EDT - 1 year ago

Lantheus Acquires Global Rights to Life Molecular Imaging's Novel Therapeutic and Diagnostic Pair Targeting GRPR for Prostate and Breast Cancers

Radiopharm Receives Strategic Investment for up to A$18 million

Jun 20, 2024, 8:41 PM EDT - 1 year ago

Radiopharm Receives Strategic Investment for up to A$18 million

RadioIsotope25
RadioIsotope25 Jul. 11 at 5:53 PM
$RADX Lutetium 177 is a blockbuster isotope fda approved for prostate cancer. Radiopharm Theranostics has 2 therapeutics using it targeting Breast and Lung cancer- they are backed by the Tesla of Radiopharmaceutical’s Lantheus having invested in January upping their position to 12% with most recent buy at the currency adjusted price of $11.75… https://www.facebook.com/share/v/1Huo4Ed5J1/?mibextid=wwXIfr $LNTH $CATX $NNE
0 · Reply
TPTradingCo
TPTradingCo Jul. 10 at 9:44 PM
$LNTH this 1-year price action funk is about to bid adieu, friend-o...
1 · Reply
RadioIsotope25
RadioIsotope25 Jul. 10 at 7:22 PM
$RADX Lantheus is moving back up nicely. $LNTH
0 · Reply
RadioIsotope25
RadioIsotope25 Jul. 8 at 1:27 PM
$LNTH Lantheus investing in this co https://m.youtube.com/watch?v=OjzgnRS7b98
0 · Reply
ChromeOnTheWheels
ChromeOnTheWheels Jul. 7 at 11:22 PM
$CPRX Impatient traders. Same story with $LNTH , another gem and long term gainer.
0 · Reply
ChromeOnTheWheels
ChromeOnTheWheels Jul. 3 at 8:50 PM
$LNTH and $CPRX are great longterm holds.
0 · Reply
RadioIsotope25
RadioIsotope25 Jul. 3 at 12:52 PM
$RADX Lantheus just bought more shares in Radiopharm Theranostics at $11.70… 7.50 upside to their buy price! Over their past 3 acquisitions they have paid $300 mil avg which implies 900% upside since market cap around $33 million. + major insider buying + tiny market cap + broad diversity in pipeline imaging and therapeutic isotopes + md anderson creating 4 new therapeutics for them + mid stage low risk brain imaging agent pivalate all signs it’s going well. + pdl-1 and her2 targeting therapeutics targeting huge billion dollar cancer markets lung cancer and breast. $INMB $LNTH
2 · Reply
RADX_enjoyer
RADX_enjoyer Jun. 24 at 1:06 PM
$RADX cashed up and kicking goals. No wonder $LNTH loves the look of Radiopharm Theranostics. Lantheus owns 12.12% of the company and continues to partner up with trials in Australia and the US!
1 · Reply
JarvisFlow
JarvisFlow Jun. 23 at 6:08 PM
B. Riley Securities updates rating for Lantheus Holdings ( $LNTH ) to Buy, target set at 122 → 109.
0 · Reply
RadioIsotope25
RadioIsotope25 Jun. 23 at 1:13 PM
$RADX The Best Buy recommendation comes from Lantheus they bought 12% of company last investment at 150% premium. Who does that? Last entry point $11.70 by $LNTH $CATX
1 · Reply
RadioIsotope25
RadioIsotope25 Jun. 20 at 2:28 PM
$LNTH last investment in $RADX was at $11.70 per share! Spread is $7.00 $CATX
0 · Reply
RadioIsotope25
RadioIsotope25 Jun. 17 at 3:30 PM
$CATX $RADX Two pubco’s backed by $LNTH
0 · Reply
DKFutureInvest
DKFutureInvest Jun. 16 at 3:21 PM
$LNTH This gonna be a handle or we going to close the gap at 67-69?
1 · Reply
RadioIsotope25
RadioIsotope25 Jun. 12 at 7:58 PM
120% upside to Lantheus last purchase. $RADX $LNTH $CATX
0 · Reply
Tyrant_
Tyrant_ Jun. 12 at 4:51 PM
$ASPI $LNTH
0 · Reply
larocqs
larocqs Jun. 11 at 2:22 PM
$LNTH Text book cup and handle
1 · Reply
RadioIsotope25
RadioIsotope25 Jun. 11 at 12:10 PM
$PSTV Rad101 fda fast tracked Lantheus invested last at $11.70 in adr equivalent $LNTH
0 · Reply
DKFutureInvest
DKFutureInvest Jun. 10 at 6:25 PM
$LNTH That handle starting today? i stillbam confused why the remaining gap is not getting filled.
1 · Reply
Jjjsn33dfulthings
Jjjsn33dfulthings Jun. 10 at 2:31 PM
$LNTH mmmmhhmmm good
0 · Reply
DKFutureInvest
DKFutureInvest Jun. 9 at 7:36 PM
$LNTH y’all think we get a handle for this cup?
1 · Reply
WAJeff
WAJeff Jun. 9 at 6:11 PM
$LNTH starting to bounce back
0 · Reply
Jjjsn33dfulthings
Jjjsn33dfulthings Jun. 9 at 4:18 PM
$LNTH slow daily grind to 90. Just hold that 70 dollar call for the 20th and sell it for 2k each that week. Bought for less the 2 bills last month
0 · Reply